知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

14 条记录 (耗时 0.019 秒)

    Product of infectious respiratory syncytial virus from cloned nucleotide sequences
    1.
    发明授权
    Product of infectious respiratory syncytial virus from cloned nucleotide sequences 失效
    来自克隆核苷酸序列的感染性呼吸道合胞病毒的产物

    公开(公告)号：US06264957B1

    公开(公告)日：2001-07-24

    申请号：US08720132

    申请日：1996-09-27

    申请人： Peter L. Collins

    发明人： Peter L. Collins

    IPC分类号： A61K39155

    CPC分类号： C07K14/005 ,  A61K39/00 ,  A61K2039/525 ,  C12N7/00 ,  C12N15/86 ,  C12N2760/18521 ,  C12N2760/18522 ,  C12N2760/18543

    摘要： Isolated polynucleotide molecules provide RSV genome and antigenomes, including that of human, bovine or murine RSV or RSV-like viruses, and chimera thereof. The recombinant genome or antigenome can be expressed with a nucleocapsid (N) protein, a nucleocapsid phosphoprotein (P), a large (L) polymerase protein, and an RNA polymerase elongation factor to produce isolated infectious RSV particles. The recombinant RSV genome and antigenome can be modified to produce desired phenotypic changes, such as attenuated viruses for vaccine use.

    摘要翻译： 分离的多核苷酸分子提供RSV基因组和抗原单体，包括人，牛或鼠RSV或RSV样病毒及其嵌合体。 重组基因组或反向原核基因组可以用核衣壳蛋白（N）蛋白，核衣壳磷蛋白（P），大（L）聚合酶蛋白和RNA聚合酶延伸因子表达，以产生分离的感染性RSV颗粒。 可以修饰重组RSV基因组和反义基因组以产生所需的表型变化，例如用于疫苗使用的减毒病毒。

    Methods for producing self-replicating infectious RSV particles comprising recombinant RSV genomes or antigenomes and the N, P, L, and M2 proteins
    2.
    发明授权
    Methods for producing self-replicating infectious RSV particles comprising recombinant RSV genomes or antigenomes and the N, P, L, and M2 proteins 有权
    用于产生包含重组RSV基因组或抗原单核细胞和N，P，L和M2蛋白质的自复制感染性RSV颗粒的方法

    公开(公告)号：US06790449B2

    公开(公告)日：2004-09-14

    申请号：US09847173

    申请日：2001-05-03

    申请人： Peter L. Collins

    发明人： Peter L. Collins

    IPC分类号： A61K39155

    CPC分类号： C07K14/005 ,  A61K39/00 ,  A61K2039/525 ,  C12N7/00 ,  C12N15/86 ,  C12N2760/18521 ,  C12N2760/18522 ,  C12N2760/18543

    摘要： RNA synthesis by the paramyxovirus respiratory syncytial virus (RSV), a ubiquitous human pathogen, was found to be more complex than previously appreciated for the nonsegmented negative-strand RNA viruses. Intracellular RNA replication of a plasmid-encoded “minigenome” analog of viral genomic RNA was directed by coexpression of the nucleocapsid (N) protein, nucleocapsid phosphoprotein (P), and the large polymerase (L) protein. But, under these conditions, it appeared that the greater part of mRNA synthesis terminated prematurely. However, coexpression of the M2 (ORF1) gene resulted in the efficient production of full-length mRNA. Thus, these results demonstrate that expression of the upstream ORF1, which encoded the previously described 22-kDa M2 protein, was associated with transcription elongation. Accordingly, the claimed invention is directed toward infectious recombinant RSV particles which comprise a recombinant genome or antigenome, as well as the RSV proteins N, P, L, and the RNA polymerase elongation factor M2. This system will permit the introduction of defined changes into infectious RSV which will prove useful in a variety of applications, such as the analysis of RSV molecular biology and pathogenesis, the development of attenuated RSV immunogenic compositions for the preparation of RSV-specific immunological reagents, and the expression of foreign antigens.

    摘要翻译： 发现通过普遍存在的人类病原体的副粘病毒呼吸道合胞病毒（RSV）的RNA合成比以前对非分段负链RNA病毒所认识的更为复杂。 病毒基因组RNA的质粒编码的“小基因组”类似物的细胞内RNA复制通过核衣壳（N）蛋白，核壳蛋白磷蛋白（P）和大聚合酶（L）蛋白的共表达来引导。 但是，在这些条件下，mRNA合成的较大部分似乎过早终止。 然而，M2（ORF1）基因的共表达导致全长mRNA的有效产生。 因此，这些结果表明编码前述的22-kDa M2蛋白的上游ORF1的表达与转录延伸有关。 因此，要求保护的发明涉及包含重组基因组或反向原子团以及RSV蛋白N，P，L和RNA聚合酶延伸因子M2的感染性重组RSV颗粒。 该系统将允许将感染性RSV引入定义的变化，这将在各种应用中有用，例如RSV分子生物学和发病机理的分析，用于制备RSV特异性免疫试剂的减毒RSV免疫原性组合物的开发， 和外源抗原的表达。

    Enhanced immune response to attachment (G) protein of Respiratory Syncytial Virus
    3.
    发明授权
    Enhanced immune response to attachment (G) protein of Respiratory Syncytial Virus 失效
    增强对呼吸道合胞病毒附着（G）蛋白的免疫反应

    公开(公告)号：US06699478B1

    公开(公告)日：2004-03-02

    申请号：US09526195

    申请日：2000-03-15

    申请人： Gerald E. Hancock ,  Paul W. Tebbey

    发明人： Gerald E. Hancock ,  Paul W. Tebbey

    IPC分类号： A61K39155

    CPC分类号： C07K14/005 ,  A61K39/00 ,  A61K2039/51 ,  C07K2319/00 ,  C12N2760/18522

    摘要： An altered G protein or portion thereof of RSV which retains immunogenicity and which, when incorporated into an immunogenic composition or vaccine and administered to a vertebrate, does not induce enhanced disease (e.g., atypical pulmonary inflammation such as pulmonary eosinophilia) upon subsequent infection with RSV, is disclosed. In a particular embodiment, the altered G protein comprises an alteration in one or more regions selected from the group consisting of the region from amino acid 159 to amino acid 198, the region from amino acid 159 to amino acid 174, the region from amino acid 171 to amino acid 187, the region from amino acid 176 to amino acid 190, and the region from amino acid 184 to amino acid 198 of the RSV G protein. Immunogenic compositions and vaccines comprising the altered RSV G protein, and optionally comprising RSV F protein, are also disclosed.

    摘要翻译： 维持免疫原性的改变的G蛋白或其部分，并且当其并入免疫原性组合物或疫苗并且施用于脊椎动物时，在随后的RSV感染时不诱导增强的疾病（例如非典型的肺部炎症，例如肺嗜酸性粒细胞增多） ，被披露。 在一个具体实施方案中，改变的G蛋白包括在一个或多个区域中的改变，所述区域选自氨基酸159至氨基酸198的区域，氨基酸159至氨基酸174的区域，氨基酸的区域 171至氨基酸187，氨基酸176至氨基酸190的区域，以及RSV G蛋白的氨基酸184至氨基酸198的区域。 还公开了包含改变的RSV G蛋白和任选地包含RSV F蛋白的免疫原性组合物和疫苗。

    Methods and compositions for inhibition of membrane fusion-associated events including RSV transmission
    6.
    发明授权
    Methods and compositions for inhibition of membrane fusion-associated events including RSV transmission 有权
    用于抑制膜融合相关事件（包括RSV传播）的方法和组合物

    公开(公告)号：US06623741B1

    公开(公告)日：2003-09-23

    申请号：US09515965

    申请日：2000-02-29

    申请人： James B. Antczak ,  Mary K. Delmedico ,  Joel B. Erickson ,  Dennis M. Lambert ,  Prakash Sista

    发明人： James B. Antczak ,  Mary K. Delmedico ,  Joel B. Erickson ,  Dennis M. Lambert ,  Prakash Sista

    IPC分类号： A61K39155

    CPC分类号： C07K14/005 ,  A61K38/00 ,  C12N2740/16122 ,  C12N2760/18522

    摘要： The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention are derived from regions of viral fusion proteins referred to as HR1 and HR2. In particular, the invention relates to peptides referred to herein as DP107 and DP178 which comprise amino acid sequences corresponding to sequences found in the HR1 and HR2 regions, respectively of the HIV-1LAI gp41 protein. The invention further relates to “DP107-like” and “DP178-like” peptides that are derived from HR1 and HR2 regions, respectively, of other proteins, including DP107-like and DP178-like peptides derived from the HR1 and HR2 regions of the F1 subunit of the respiratory syncytial virus fusion protein.

    摘要翻译： 本发明涉及显示出有力的抗​​逆转录病毒活性的肽。 本发明的肽衍生自称为HR1和HR2的病毒融合蛋白的区域。 特别地，本发明涉及本文称为DP107和DP178的肽，其包含分别对应于HIV-1LAI gp41蛋白质的HR1和HR2区域中发现的序列的氨基酸序列。 本发明还涉及分别来自其它蛋白质的HR1和HR2区域的“DP107样”和“DP178样”肽，其包括源自其的HR1和HR2区的DP107样和DP178样肽 F1亚基的呼吸道合胞病毒融合蛋白。

    Nucleotide sequence for the Avian Metapneumovirus (Colorado) attachment glycoprotein gene
    7.
    发明授权
    Nucleotide sequence for the Avian Metapneumovirus (Colorado) attachment glycoprotein gene 失效
    禽类亚型肺炎病毒（科罗拉多州）附着糖蛋白基因的核苷酸序列

    公开(公告)号：US06605283B1

    公开(公告)日：2003-08-12

    申请号：US10285626

    申请日：2002-11-01

    申请人： Bruce S. Seal ,  Rene Alvarez

    发明人： Bruce S. Seal ,  Rene Alvarez

    IPC分类号： A61K39155

    CPC分类号： C07K14/005 ,  C12N2760/18322

    摘要： The nucleic acid and the corresponding amino acid sequence for the attachment glycoprotein of Avian Metapneumovirus (Colorado) Type C strain is provided. The nucleotide sequence is 1,321 base pairs with only one substantial open reading frame encoding a glycoprotein of about 435 amino acids with a predicted Mr of about 48,483 and a net charge of about 23.15 at neutral pH.

    摘要翻译： 提供了禽类亚型肺炎病毒（Colorado）C型毒株附着糖蛋白的核酸和相应的氨基酸序列。 核苷酸序列是1321个碱基对，仅具有编码约435个氨基酸的糖蛋白的一个基本开放阅读框，预测的Mr约为48,483，中性pH下的净电荷约为23.15。

    Nucleotide sequences encoding bovine respiratory syncytial virus immunogenic proteins
    10.
    发明授权
    Nucleotide sequences encoding bovine respiratory syncytial virus immunogenic proteins 失效
    编码牛呼吸道合胞病毒免疫原性蛋白的核苷酸序列

    公开(公告)号：US06730305B1

    公开(公告)日：2004-05-04

    申请号：US09567458

    申请日：2000-05-08

    申请人： Gail W. Wertz ,  Robert Lerch

    发明人： Gail W. Wertz ,  Robert Lerch

    IPC分类号： A61K39155

    CPC分类号： C07K14/005 ,  A61K38/00 ,  A61K39/00 ,  A61K39/12 ,  A61K39/155 ,  A61K2039/5256 ,  C12N2710/24143 ,  C12N2760/18522 ,  C12N2760/18534

    摘要： The present invention relates to recombinant DNA molecules which encode bovine respiratory syncytial (BRS) virus proteins, to BRS virus proteins, and peptides and to recombinant BRS virus vaccines produced therefrom. It is based, in part, on the cloning of substantially full length cDNAs which encode the entire BRS virus G, F, and N proteins. According to particular embodiments of the invention, DNA encoding a BRS virus protein or peptide may be used to diagnose BRS virus infection, or, alternatively, may be inserted into an expression vector, including, but not limited to, vaccinia virus as well as bacterial, yeast, insect, or other vertebrate vectors. These expression vectors may be utilized to produce the BRS virus protein or peptide in quantity; the resulting substantially pure viral peptide or protein may be incorporated into subunit vaccine formulations or may be used to generate monoclonal or polyclonal antibodies which may be utilized in diagnosis of BRS virus infection or passive immunization. In additional embodiments, BRS virus protein sequence provided by the invention may be used to produce synthetic peptides or proteins which may be utilized in subunit vaccines, or polyclonal or monoclonal antibody production. Alternatively, a nonpathogenic expression vector containing the genes, parts of the genes, any combination of the genes, or parts thereof may itself be utilized as a recombinant virus vaccine.

    摘要翻译： 本发明涉及编码牛呼吸道合胞体（BRS）病毒蛋白质，BRS病毒蛋白质的重组DNA分子，以及由其产生的重组BRS病毒疫苗。 其部分基于克隆编码整个BRS病毒G，F和N蛋白的基本上全长的cDNA。 根据本发明的具体实施方案，编码BRS病毒蛋白或肽的DNA可用于诊断BRS病毒感染，或者可以将其插入到表达载体中，包括但不限于痘苗病毒以及细菌 ，酵母，昆虫或其他脊椎动物载体。 这些表达载体可以用来量产BRS病毒蛋白或肽; 所得到的基本上纯的病毒肽或蛋白质可以并入亚单位疫苗制剂中，或可用于产生可用于诊断BRS病毒感染或被动免疫的单克隆或多克隆抗体。 在另外的实施方案中，本发明提供的BRS病毒蛋白质序列可用于产生可用于亚单位疫苗或多克隆或单克隆抗体产生的合成肽或蛋白质。 或者，含有基因，部分基因，基因的任何组合或其部分的非致病性表达载体本身可以用作重组病毒疫苗。